Heritage Investors Management Corp Sells 6,886 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Heritage Investors Management Corp cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,959 shares of the medical equipment provider’s stock after selling 6,886 shares during the period. Heritage Investors Management Corp owned 0.07% of Zimmer Biomet worth $11,480,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. DV Equities LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $32,000. Finally, Grove Bank & Trust grew its position in shares of Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZBH. Barclays decreased their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. JPMorgan Chase & Co. dropped their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Robert W. Baird set a $92.00 target price on Zimmer Biomet in a research report on Wednesday, April 29th. Citizens Jmp decreased their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $102.70.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $87.50 on Friday. The company’s fifty day moving average price is $86.20 and its 200-day moving average price is $89.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $16.93 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 2.48 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the firm posted $1.81 EPS. The firm’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.